Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in CanadaGRIMA, Daniel T; THOMPSON, Melissa F; SAURIOL, Luc et al.PharmacoEconomics (Auckland). 2007, Vol 25, Num 3, pp 253-266, issn 1170-7690, 14 p.Article

Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes MellitusBROWN, Stephen T; GRIMA, Daniel Grima; SAURIOL, Luc et al.Clinical therapeutics. 2014, Vol 36, Num 11, pp 1576-1587, issn 0149-2918, 12 p.Article

Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile InfectionMILLER, Mark; BERNARD, Lisa; THOMPSON, Melissa et al.Infection control and hospital epidemiology. 2010, Vol 31, Num 7, pp 710-715, issn 0899-823X, 6 p.Article

An economic evaluation of rizatriptan in the treatment of migraineTHOMPSON, Melissa; GAWEL, Marek; DESJARDINS, Brigitte et al.PharmacoEconomics (Auckland). 2005, Vol 23, Num 8, pp 837-850, issn 1170-7690, 14 p.Article

Projected clinical benefits and cost-effectiveness of a Human papillomavirus 16/18 vaccineGOLDIE, Sue J; KOHLI, Michele; GRIMA, Daniel et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 8, pp 604-615, issn 0027-8874, 12 p.Article

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysisHUTCHISON, Colin A; HEYNE, Nils; AIRIA, Parisa et al.Nephrology, dialysis, transplantation (Print). 2012, Vol 27, Num 10, pp 3823-3828, issn 0931-0509, 6 p.Article

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccineGOLDIE, Sue J; GRIMA, Daniel; KOHLI, Michele et al.International journal of cancer. 2003, Vol 106, Num 6, pp 896-904, issn 0020-7136, 9 p.Article

Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysisGRIMA, Daniel T; DUNN, Elizabeth S; BERNARD, Lisa M et al.Current medical research and opinion. 2013, Vol 29, Num 2, pp 109-115, issn 0300-7995, 7 p.Article

The Authors' Reply to van Baal et al.: Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et alGRIMA, Daniel T; BERNARD, Lisa M; DUNN, Elizabeth S et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 5, pp 375-376, issn 1170-7690, 2 p.Article

Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis: A Case for Excluding Dialysis CostsGRIMA, Daniel T; BERNARD, Lisa M; DUNN, Elizabeth S et al.PharmacoEconomics (Auckland). 2012, Vol 30, Num 11, pp 981-989, issn 1170-7690, 9 p.Article